A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease

Greenblatt, 1999, Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 Å resolution, FEBS Lett, 463, 321, 10.1016/S0014-5793(99)01637-3

Storch, 1995, Physostigmine, galanthamine and codeine act as ‘noncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cells, Eur J Pharmacol, 290, 207, 10.1016/0922-4106(95)00080-1

Maelicke, 2000, Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease, Behav Brain Res, 113, 199, 10.1016/S0166-4328(00)00214-X

Raskind, 2000, Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension, Neurology, 54, 2261, 10.1212/WNL.54.12.2261

Tariot, 2000, A 5-month randomized, placebo-controlled trial with a 6-month extension, Neurology, 54, 2269, 10.1212/WNL.54.12.2269

Wilcock, 2000, Galantamine alleviates caregiver burden in Alzheimer's disease: a 6-month placebo-controlled study, Neurobiol Aging, 21, S241, 10.1016/S0197-4580(00)83423-5

Wilkinson, 2001, Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease, Int J Geriatr Psychiatry, 16, 852, 10.1002/gps.409

McKhann, 1984, Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA work group under the auspices of the Department of Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939

Folstein, 1975, Mini-mental state. A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6

Cummings, 1994, The neuropsychiatric inventory, Neurology, 44, 2308, 10.1212/WNL.44.12.2308

Kaufer, 1998, Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale, J Am Geriatr Soc, 46, 210, 10.1111/j.1532-5415.1998.tb02542.x

Bucks, 1996, Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale, Age Ageing, 25, 113, 10.1093/ageing/25.2.113

Drug Therapy Bulletin., 1998, Donepezil update, Drug Ther Bull, 36, 60, 10.1136/dtb.1998.36860

Teri, 1989, Behavioural disturbance, cognitive dysfunction and functional skill: prevalence and relationship in Alzheimer's disease, J Am Geriatr Soc, 37, 109, 10.1111/j.1532-5415.1989.tb05868.x

Brodarty, 1993, Time until institutionalisation and death in patients with dementia, Arch Neurol, 50, 643, 10.1001/archneur.1993.00540060073021

The Canadian Study of Health and Aging., 1994, Patterns of caring for people with dementia in Canada, Can J Aging, 13, 470, 10.1017/S0714980800006334

Kaufer, 1996, Effects of tacrine on behavioural symptoms in Alzheimer's disease: an open-label study, J Geriatr Psychiatry Neurol, 9, 1, 10.1177/089198879600900101

Morris, 1998, Metrifonate benefits cognitive, behavioural, and global function in patients with Alzheimer's disease, Neurology, 50, 1222, 10.1212/WNL.50.5.1222

Mega, 1999, The spectrum of behavioural responses to cholinesterase inhibitor therapy in Alzheimer's disease, Arch Neurol, 56, 1388, 10.1001/archneur.56.11.1388

Raskind, 1999, The effects of metrifonate on the cognitive, behavioural, and functional performance of Alzheimer's disease patients, J Clin Psychiatry, 60, 318, 10.4088/JCP.v60n0510

Rösler, 1999, Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial, BMJ, 318, 633, 10.1136/bmj.318.7184.633

De Deyn, 1999, A randomized trial of risperidone, placebo, and haloperidol for behaviour symptoms in dementia, Neurology, 53, 946, 10.1212/WNL.53.5.946

Katz, 1999, Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomized, double-blind trial, J Clin Psychiatry, 60, 107, 10.4088/JCP.v60n0207

Knapp, 1994, A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease, JAMA, 271, 985, 10.1001/jama.1994.03510370037029

Antuono, 1995, Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study, Arch Intern Med, 155, 1766, 10.1001/archinte.1995.00430160102010

Rogers, 1998, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease, Neurology, 50, 136, 10.1212/WNL.50.1.136

Burns, 1999, The effects of donepezil in Alzheimer's disease: results from a multinational trial, Dement Geriatr Cogn Disord, 10, 237, 10.1159/000017126